Companies Dominating the Cerebral Artery Syndrome Treatment Landscape
- Bristol Myers Squibb
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Athersys, Inc.
- Janssen Pharmaceuticals, Inc
- Royal Philips
- AstraZeneca plc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cerebral artery syndrome treatment is estimated at USD 2.24 billion.
The cerebral artery syndrome treatment market size was valued at USD 2.13 billion in 2024 and is set to exceed USD 4.71 billion by 2037, registering over 6.3% CAGR during the forecast period i.e., between 2025-2037. Growing research and development activities, rising technological advancements in healthcare industry, and increasing awareness among the individuals will drive the market growth.
North America industry is set to account for largest revenue share of 35% by 2037, due to growing awareness among individuals regarding minimally invasive stroke treatment.
The major players in the market are Bristol Myers Squibb, Athersys, Inc., Janssen Pharmaceuticals, Inc, Royal Philips, AstraZeneca plc, Daiichi Sankyo Company, Limited, LIFESCAPES Inc, Shionogi & Co., Ltd., Fujitsu, Takeda Pharmaceutical Co Ltd and others.
